The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.

Journal article

OBJECTIVES: This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. BACKGROUND: There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. METHODS: The e-SELECT (Multicenter Post-Market Surveillance) registry...

Expand abstract

Authors: Abizaid, A; Costa, JR; Banning, A; Bartorelli, A; Dzavik, V

• Journal: JACC. Cardiovascular interventions
• Volume: 5
• Issue: 1
• Pages: 64-71
• Publication date: 2012-01-01
• DOI: 10.1016/j.jcin.2011.09.016
• EISSN: 1876-7605
• ISSN: 1936-8798
• Language: English
• Keywords: Sirolimus; Angioplasty, Balloon, Coronary; Multivariate Analysis; Registries; Female; Health Status Indicators; Drug-Eluting Stents; Kaplan-Meier Estimate; Male; e-SELECT Investigators; Coronary Restenosis; Europe; Humans; Immunosuppressive Agents; Statistics as Topic; Middle Aged; Product Surveillance, Postmarketing; Databases, Factual; Internationality